Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.


The Diabetes Prevention Program (DPP) was a randomized clinical trial of prevention of type 2 diabetes in high-risk people. Troglitazone, an insulin-sensitizing agent, was used initially but was discontinued during the trial. Troglitazone therapy was compared with other DPP interventions, considering both the short-term "in-trial" results and the longer… (More)


6 Figures and Tables

Blog articles referencing this paper